# US 2024/0390508 A1 · Human transferrin receptor binding peptide-drug conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390508 A1
- Document ID: US20240390508A1
- Status: Published application
- Kind: A1
- Application number: 18/685,457
- Filed: 2022-08-19
- Published: 2024-11-28
- Earliest claimed: 2021-08-21
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Takatoshi YOGO; Hideyuki SUGIYAMA; Kenichi MIYATA; Hiroyuki TAKADA; Masato YOSHIDA; Ryosuke TOKUNOH; Yasuo NAKAGAWA; Masato NIWA; Shigekazu SASAKI; Masaki OHUCHI; Naoki SAWAI; Masatoshi TAKUWA; Yujiro UCHINO; Yoko KANEMATSU; Koichiro FUKUDA; Takanori YOKOTO; Tetsuya NAGATA; Hiroki YAMADA
- Web page: https://patentgrep.com/patent/US20240390508A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K 38/1719: {Muscle proteins, e.g. myosin or actin}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 48/0033: {the non-active part being non-polymeric}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/11: Antisense
- C12N 2310/314: Phosphoramidates
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/3513: Protein; Peptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.

## Claims

### Claim 1

A conjugate or a salt thereof comprising the following:
(1) a peptide that binds to a transferrin receptor, and comprises
the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or
an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and
(2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.

### Claim 2 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein
the peptide that binds to a transferrin receptor is a peptide comprising
the amino acid sequence shown in SEQ ID NO: 296 (Ala-Val-MeF-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Arg-Arg-Tyr-MeY-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 296.

### Claim 3 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein
the peptide that binds to a transferrin receptor is a peptide comprising
the amino acid sequence shown in SEQ ID NO: 296; or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 5 amino acid residues in the amino acid sequence shown in SEQ ID NO: 296.

### Claim 4 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the peptide that binds to a transferrin receptor is a peptide comprising
the amino acid sequence shown in SEQ ID NO: 296; or an amino acid sequence resulting from substitution of any of the 3rd, 5th, 7th, 8th, 11th, 12th, and 13th amino acid residues of the SEQ ID NO: 296.

### Claim 5 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the peptide that binds to a transferrin receptor is any of peptides in which
the 3rd amino acid residue of SEQ ID NO: 296 is an optionally modified phenylalanine (Phe),
the 5th amino acid residue of SEQ ID NO: 296 is an optionally modified tryptophan (Trp),
the 7th amino acid residue of SEQ ID NO: 296 is an optionally modified tyrosine (Tyr),
the 8th amino acid residue of SEQ ID NO: 296 is an optionally modified tyrosine (Tyr),
the 11th amino acid residue of SEQ ID NO: 296 is an optionally modified arginine (Arg) or an optionally modified lysine (Lys),
the 12th amino acid residue of SEQ ID NO: 296 is an optionally modified arginine (Arg) or an optionally modified lysine (Lys), or
the 13th amino acid residue of SEQ ID NO: 296 is an optionally modified tyrosine (Tyr) or an optionally modified phenylalanine (Phe).

### Claim 6 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the peptide that binds to a transferrin receptor is a peptide in which
the 3rd amino acid residue of SEQ ID NO: 296 is phenylalanine (Phe), methylated phenylalanine (MeF), or N-methyl-3-chloro-L-phenylalanine (MeF3C),
the 5th amino acid residue of SEQ ID NO: 296 is tryptophan (Trp) or methylated tryptophan (MeW),
the 7th amino acid residue of SEQ ID NO: 296 is tyrosine (Tyr),
the 8th amino acid residue of SEQ ID NO: 296 is tyrosine (Tyr) or (S)-2-amino-3-(4-methoxyphenyl)propanoic acid (F4OMe),
the 11th amino acid residue of SEQ ID NO: 296 is arginine (Arg) or lysine (Lys),
the 12th amino acid residue of SEQ ID NO: 296 is arginine (Arg) or D-type arginine (dr), and
the 13th amino acid residue of SEQ ID NO: 296 is tyrosine (Tyr) or phenylalanine (Phe).

### Claim 7 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the peptide that binds to a transferrin receptor is a cyclic peptide.

### Claim 8 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the peptide that binds to a transferrin receptor consists of 15 amino acid residues.

### Claim 9 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the peptide that binds to a transferrin receptor is a peptide consisting of the 1st to the 15th amino acid sequences, and the amino acid sequence site has a cyclic structure.

### Claim 10 (depends on 1)

The conjugate or a salt thereof according to claim 1 wherein the oligonucleotide is an oligonucleotide that induces exon skipping of the dystrophin gene.

### Claim 11 (depends on 10)

The conjugate or a salt thereof according to claim 10, wherein the exon is selected from exon 7, exon 8, exon 9, exon 19, exon 23, exon 44, exon 45, exon 46, exon 50, exon 51, exon 52, exon 53, exon 55, or any combination of these exons.

### Claim at position 12

-13. (canceled)

### Claim 14 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein a sugar moiety and/or a phosphate binding site of at least one nucleotide constituting the compound comprising an oligonucleotide is modified.

### Claim 15 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the compound comprising an oligonucleotide comprises an antisense oligonucleotide of 10 to 35 bases in length.

### Claim 16 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the compound comprising an oligonucleotide comprises an antisense oligonucleotide of 16 to 30 bases in length.

### Claim 17 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the compound comprising an oligonucleotide comprises an antisense oligonucleotide of 18 to 25 bases in length.

### Claim 18 (depends on 15)

The conjugate or a salt thereof according to claim 15, wherein the antisense oligonucleotide comprises a sequence complementary to 12 or more continuous nucleotides in the target region of dystrophin mRNA.

### Claim 19 (depends on 18)

The conjugate or a salt thereof according to claim 18, wherein the target region of the dystrophin mRNA is
(SEQ ID NO: 647)
TACAAGAACACCTTCAGAACCGGAGGCAACAGTTG.

### Claim 20 (depends on 15)

The conjugate or a salt thereof according to claim 15, wherein the antisense oligonucleotide consists of a sequence complementary to GAACACCTTCAGAACCGGAGGCAAC (SEQ ID NO: 648) or GAACACCTTCAGAACCGGAGG (SEQ ID NO: 649).

### Claim 21

(canceled)

### Claim 22 (depends on 18)

The conjugate or a salt thereof according to claim 18, wherein the complementary sequence is not less than 90% complementary.

### Claim 23 (depends on 18)

The conjugate or a salt thereof according to claim 18, wherein the complementary sequence is 100% complementary.

### Claim 24 (depends on 15)

The conjugate or a salt thereof according to claim 15, wherein the antisense oligonucleotide is a phosphorodiamidatemorpholino oligomer.

### Claim 25 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the compound comprising an oligonucleotide is a compound composed of an antisense oligonucleotide.

### Claim 26 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the compound comprising an oligonucleotide consists of a nucleic acid complex comprising an antisense oligonucleotide and a second nucleic acid strand complementary to all or part of the antisense oligonucleotide, wherein the antisense oligonucleotide anneals to the second nucleic acid strand.

### Claim 27 (depends on 1)

The conjugate or a salt thereof according to claim 1, wherein the peptide and the compound comprising an oligonucleotide are bound via a linker.

### Claim at position 27

-31. (canceled)

### Claim 32 (depends on 1)

A method for the prophylaxis or treatment of Duchenne muscular dystrophy in a mammal, comprising administering the conjugate or a salt thereof according to claim 1 to the mammal.
